Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2025-03-03 Regulatory Filings
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces updates regarding clinical trial data (NCX 470 Mont Blanc Trial) and development timelines (NDA submission targeted for H1 2026). This format, focusing on recent operational and scientific news rather than comprehensive annual financials (10-K) or detailed quarterly results (IR), strongly suggests an Earnings Release (ER) or a general announcement. Since it is a detailed update on clinical progress and future filings, and not just a summary of financial performance, it fits best as a general corporate announcement. However, given the context of providing scientific updates and development milestones, it is a form of corporate communication. It is not a transcript (CT), a formal annual report (10-K), or a specific regulatory filing like DIRS or DIV. Because it is a press release detailing operational/scientific progress, it is most closely aligned with an Earnings Release (ER) which often includes operational updates alongside any financial context, or potentially a Regulatory Filing (RNS) if it were less specific. Given the structure and content (key highlights, CSO quote, development update), ER is the most appropriate fit among the specific operational codes, as these releases often accompany or precede formal financial reporting periods.
2025-03-03 English
Nicox présente une nouvelle analyse de l'étude NCX 470 Mont Blanc et fournit une mise à jour sur son développement
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and is dated March 3, 2025. It announces new analysis results from a Phase 3 study (Mont Blanc) for a drug candidate (NCX 470) and provides a development update, including expected timelines for NDA submission and results from other trials (Whistler, Denali). This format—a brief announcement summarizing key findings, often referencing a presentation at a conference (AGS Annual Meeting), and providing business updates—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy (DEF 14A), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede formal earnings announcements, or serve as major operational updates. It is not an RPA because it contains substantial new data and analysis, not just an announcement that a report is available. It is a direct communication of results/updates.
2025-03-03 French
Nicox : Présentation Scientifique et Participation aux Congrès du premier semestre 2025
Regulatory Filings Classification · 1% confidence The document is a press release from Nicox SA announcing their upcoming scientific presentations at medical congresses and participation in investor conferences for the first half of 2025. It does not contain financial results, board changes, or regulatory filings, but rather serves as a general corporate update regarding company activities and events. As it does not fit into specific categories like earnings releases or investor presentations, it falls under the general regulatory announcement category.
2025-01-28 French
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
Regulatory Filings Classification · 1% confidence The document is a press release from Nicox SA announcing upcoming scientific presentations and attendance at various investor and medical conferences in the first half of 2025. It does not contain financial results, board changes, or specific regulatory filings, but rather serves as a general corporate update regarding company activities and event participation. As it does not fit into more specific categories like Earnings Release or Investor Presentation (which would contain the actual slides/data), it is best classified as a general regulatory announcement.
2025-01-28 English
Nicox confirme son éligibilité au PEA-PME
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a confirmation regarding the company's eligibility for the PEA-PME investment scheme, citing specific articles of the French monetary and financial code. It is a short, specific announcement dated January 22, 2025, providing a brief update rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT). It does not fit the definitions for AGM-R, ER, DIV, or DIRS. Since it is a specific regulatory/market status update that doesn't fit the other specialized categories (like M&A, Capital Change, or Dividend), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous official announcements not covered elsewhere. Given its nature as a press release confirming a regulatory status, RNS (Regulatory Filings) is the most appropriate classification.
2025-01-22 French
Nicox : Point d’activité et résumé financier du quatrième trimestre 2024
Earnings Release Classification · 1% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and presents a "Point d'activité et résumé financier du quatrième trimestre 2024" (Activity update and financial summary for the fourth quarter of 2024). It highlights key financial figures (revenue, cash position) and clinical trial milestones for Q4 2024, with forward-looking statements. This format, providing key highlights immediately following the end of a reporting period, strongly indicates an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it explicitly states it does not present consolidated financial statements but rather a summary. It is also not a Report Publication Announcement (RPA) because it contains the actual summary data, not just an announcement that a report is forthcoming. Q4 2024
2025-01-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.